Study identifier:MI-CP223
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Prospective Observational Study to Assess the Role of Selected Biomarkers in Subjects Requiring Daily Medium- to High-dose Inhaled Corticosteroids for Persistent Asthma
asthma
N/A
No
-
All
97
Observational
18 Years - 75 Years
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Not applicable
Masking: Not applicable
Primary Purpose: -
Verified 01 Oct 2012 by MedImmune, LLC
MedImmune, LLC
-
The rationale for conducting this study is to explore potential clinical and peripheral biomarkers in subjects requiring daily medium to high dose inhaled corticosteroids for persistent asthma
Location
Location
Calgary, AB, Canada
Location
Rochester, MN, United States
Location
Chapel Hill, NC, United States
Location
St. Louis, MO, United States
Location
Denver, CO, United States
Location
Galveston, TX, United States
Location
Pittsburg, PA, United States
Location
Columbus, OH, United States
Arms | Assigned Interventions |
---|---|
Cohort 1 50 eosinophilic subjects to be evaluated | Other: No drug will be used Biomarker |
Cohort 2 50 non-eosinophilic subjects to be evaluated | Other: No drug will be used Biomarker |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.